Illumina's NovaSeq accessory, which it plans to launch in Q4, will enable customers to run different experiments and library types in different flow cell lanes.
The partners will commercialize Counsyl's Expanded Carrier Screening Test as preconGen, beginning in Spain, Italy, Portugal, Switzerland, and Colombia.
The company hopes to accrue around 5,000 patients over the next few years, creating a broad dataset coupling outcomes with comprehensive DNA, RNA, and protein analyses.
Grail plans to enroll up to 120,000 women who have been screened via mammogram, to train and validate its NGS-based early detection cancer test.
Sync for Genes seeks to leverage HL7 FHIR infrastructure to communicate information from clinical genomic labs in a format for universal use across medicine.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.
This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.